Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 11/20 | 0.49 |
| ▸ | KCNJ3 | P48549 | 11/20 | 0.49 |
| ▸ | KCNJ5 | P48544 | 5/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657904 | 0.80 | TRPV1 (0.46) | TRPV1GAA | |
| SCHEMBL25510548 | 0.76 | KCNJ6 (0.51) | KCNJ6KCNJ3KCNJ5TRPV1NPC1 | |
| SCHEMBL4069114 | 0.75 | KCNJ6 (0.53) | KCNJ6KCNJ3KCNJ5TRPV1NPC1 | |
| SCHEMBL4069116 | 0.74 | MEN1 (0.57) | KCNJ6KCNJ3KCNJ5PKMGAA | |
| SCHEMBL657576 | 0.72 | TRPV1 (0.38) | TRPV1LMNATP53PKMGAA | |
| SCHEMBL657732 | 0.71 | TRPV1 (0.44) | TRPV1LMNAPKMSMN1; SMN2GAA | |
| SCHEMBL660095 | 0.70 | MAPK14 (0.48) | GAA | |
| SCHEMBL12506455 | 0.70 | KCNJ6 (0.53) | KCNJ6KCNJ3KCNJ5TRPV1PKM | |
| SCHEMBL671245 | 0.69 | KCNJ6 (0.48) | KCNJ6KCNJ3KCNJ5TRPV1NPC1 | |
| SCHEMBL659630 | 0.69 | KLKB1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | GRUENENTHAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | TRPV1, CNR1, CNR2 | KCNJ6 882/4885KCNJ3 902/4885KCNJ5 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.